Faculty and Disclosure: Gary Hudes, MD
Fox Chase Cancer Center
Philadelphia, PA
• Consultant or Advisory Role: GlaxoSmithKline, Genentecher Ming Hui Chen, MD
Brigham and Women's Hospital Boston, MA
• Consultant or Advisory Role: AstraZeneca Program Planners: Richard M. Steingart, MD, FACC
Chief, Cardiology Service, Memorial Sloan-Kettering Cancer Center, New York, NY
• Consultant or Advisory Role: Pfizer, Celgene Sandra M. Swain, MD
Medical Director, Washington Cancer Institute
Washington Hospital Center
Washington, DC
• Consultant or Advisory Role: Genentech, sanofi-aventis; Research Funding: BiPar Sciences, Bristol Myers Squibb, Genetech, Novartis, Roche, Wyeth; Other Renumeration: Genentech, sanofi-aventis |
Program Title:
Cardiac Co-Morbidity Board (Module 3 of 3): Tyrosine Kinase Inhibitor Toxicities 
Issued: 12/7/2011
CME/CE term of approval: 12/7/2012
Estimated Time to Complete Activity: 1 hour Hardware/Software Requirements:
• A Windows or Apple Mac Computer
• An Internet Connection (Broadband Recommended)
• Firefox 1.1+, Internet Explorer 5.0+, or Safari 1.0+
• Flash Player 7.0+ Recommended
• Adobe Reader for opening PDF files
(Available for free download from www.adobe.com) Statement of Need:
Cancer patients have often been excluded from studies of CVD and patients with significant CVD have been excluded from studies of new cancer therapies. Consequently, the ability to determine the incidence or prevalence of cardiovascular toxic effects of anticancer agents and to determine their optimal management has been limited. ACGME Competencies addressed: - Medical Knowledge
- Patient Care
Target Audience:
Primary - oncologists and cardiologists; fellows in each sub-specialty. Secondary - NPs, PAs that are in oncology or cardiology practice settings. Learning Objectives:
After completing this eLearning activity, participants should be able to:
 Enhance awareness of the different types of tyrosine kinase inhibitor (TKI)-associated cardiotoxicities, specifically for sunitinib in the treatment of renal cell carcinoma.
Describe the various mechanisms of cardiotoxicity from TKIs.
Identify and assess patients at high-risk for cardiotoxicity from TKIs.
Apply treatment management strategies for patients experiencing cardio toxic effects from TKI anti-cancer treatment.
Discuss the treatment approaches for other TKIs. CME Accreditation Statement:
The American Society of Clinical Oncology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Credit Designation:
The American Society of Clinical Oncology® designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Disclosure and Unlabelled Usage Statement:
The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and/or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.
Contact Information: - For technical assistance, contact ASCO Technical Support at 888-273-3508 (in the U.S.), 571-483-1524 (outside the U.S.), or via email at university@asco.org.
- For CME certificate requests or other CME-related questions, contact ASCO CME Staff at 571-483-1403, or via email at cme@asco.org
- For all other products or general Customer Service questions, contact ASCO Customer Service at 888-273-3508 (in the U.S.), 703-519-1430 (outside the U.S.), or via email at onlinelearning@asco.org.
Sponsored by:
This activity is cosponsored by the American Society of Clinical Oncology® and the American College of Cardiology Foundation. Method of Participation
All components of this module are hosted on the eLearning platform, ASCO University®. Prior to viewing the module content, participants should review the CME information, target audience statement, module learning objectives and faculty disclosure information. Participants will review the case scenario and listen to the accompanying audio commentary, read the references and resources, participate in the discussion forum, and complete the evaluation while online.
Obtaining Continuing Medical Education Credit
To receive CME credit, participants must complete the Self-Assessment, Evaluation and Request for CME Credit by using the online submission button within this activity. Certificates will be available immediately upon completion of the assessment, evaluation and request for credit. For more information on ASCO’s CME Activities, please visit www.asco.org/cme. 
|